The central estimate is that B.1.1.7 carries a 30 to 40 per cent higher chance of dying. The impact of this relative risk on an individual will depend critically on his or her absolute risk — determined above all by age and then by underlying health and other factors. The evidence considered by Nervtag suggests that the variant increases case fatality rates consistently across all age groups.